Myostatin Inhibitors Can Build Bigger Muscles — But Not Stronger Ones
Myostatin inhibitor trials add muscle mass on MRI without gains in grip strength or walk tests. Peter Attia's four hypotheses for why size and function split.
Peter Attia's Framework for Prioritizing Health Interventions — What's High-Impact vs. Optimization
Peter Attia separates foundation interventions (exercise, sleep, nutrition) from optimizations like supplements, judged by effect size and trade-offs.
Peter Attia on Thyroid Health: Why 5% of Adults Are Mismanaged, TSH Isn't the Full Picture, and What to Do When Tests Look Normal But You Don't
In AMA #89, Peter Attia addresses thyroid dysfunction — one of medicine's most commonly mismanaged conditions. TSH measures pituitary signaling, not tissue-level T3 activity. He stakes out the messy middle between under-treatment and over-treatment camps, with a framework for evaluating subclinical dysfunction and persistent symptoms with normal tests.
Blood Pressure and Longevity: What Peter Attia's AMA #48 Gets Right About Measurement
Blood pressure is one of three primary drivers of atherosclerosis — yet most people check it once a year. Attia's AMA #48 rebroadcast makes the case for treating it as a daily metric.
Zone 2 Training: Why Time-Constrained Athletes May Be Better Off Skipping It
Peter Attia reframes Zone 2 as a volume tool, not a metabolic must-do — and the implications for busy people are bigger than expected.
Gum Recession: Why the Habits You Think Are Helping May Be Hurting
Gum recession affects 88% of adults 65+, and aggressive brushing is a leading cause. Why lost gum tissue never grows back — and the one technique change that matters.
Peptides: Peter Attia's Framework for Separating Science from Marketing
Peter Attia's episode #403 gives biohackers a rigorous 5-question test for evaluating peptides — and most gray-market compounds fail at question one.
Protein Restriction for Kidney Disease: What the Evidence Actually Shows
Peter Attia reviews the MDRD trial and Cochrane data: the default CKD advice to restrict protein lacks the evidence base it's been given — and the biggest trial showed higher long-term mortality in the restriction group.
NMR Blood Testing: One Blood Sample, Four Different Risk Scores
A single NMR blood scan reveals heart disease, insulin resistance, inflammation, and mortality risk — the inventor explains why one draw beats a standard panel.
Peter Attia's Framework for Environmental Threats to Longevity: Air, Noise, and Light
AMA #87 applies Attia's 80/20 principle to chronic environmental exposures — PM2.5, noise, and artificial light — and which interventions actually move the longevity needle.
Heat Training Boosts Hemoglobin — But Can It Make You Faster?
Heat training reliably raises hemoglobin mass by 2–5%. But 5 of 6 trials find no clear performance payoff in VO₂max or sport results. Here's what the evidence actually shows.
Does Losing Sleep Mean Losing Lifespan? What the Meta-Analysis Can't Tell You
A new 79-study meta-analysis links short sleep to 14% higher mortality — but Peter Attia identifies a fundamental problem with the data. Here's what the observational evidence actually proves, and what the controlled research says instead.
Peter Attia: High HDL Cholesterol Doesn't Protect Your Heart. It Might Hurt It.
HDL-C has been called 'good cholesterol' for decades. Peter Attia's latest analysis unpacks why the clinical evidence never supported the label — and why very high HDL-C levels may signal elevated cardiovascular risk, not lower.
Lung Cancer Screening for Never-Smokers: What the Data Says
Guidelines don't recommend lung cancer screening for never-smokers — but the evidence gap is a policy artifact, not a scientific finding. Peter Attia makes the case for personalized assessment.
The Breast Cancer Screening Framework Peter Attia Uses — And Why Standard Mammogram Advice Falls Short
Risk-stratified screening starts with a formal risk assessment by age 25 — not when your doctor first orders a mammogram at 40. Peter Attia's framework explains why, and what the implementation failure actually looks like at scale.
Sleep Pharmacology: Why Most Sleep Drugs Don't Deliver What You Think
Peter Attia's Episode 394 tackles which sleep medications actually work and which only sedate. The core insight — sedation is not sleep — reframes how to think about every drug in this category.
77% of Max Strength Gains With Light Weights Twice a Week
A meta-analysis of 192 studies finds that light-load, multi-set training twice a week captures 77% of maximal strength gains. The gap between optimal and accessible is far smaller than the fitness industry suggests.
Peter Attia's Three-Question Framework for Cutting Through Supplement Noise
Peter Attia's AMA #85 framework for supplement evaluation: define the problem precisely, measure with a biomarker, and weigh risk against reward honestly.
4 Genetic Tests Worth Getting — And Why Most Aren't
Peter Attia's Episode #392 framework on genetic testing: the four high-penetrance tests that actually change clinical decisions, and why most DTC tests don't.
Peter Attia AMA #84: Family History, NAD Skepticism, and Dementia Risk
Peter Attia AMA #84: why family health history outperforms genetic testing, his stance on NAD supplements, and minimum effective strength training dose.
Rapamycin + Exercise: Why the First Real Trial Disappointed
Rapamycin may blunt exercise gains in older adults. Peter Attia: this trial is underpowered—but the HbA1c signal is real.
Peptides: Peter Attia Separates the Science From the Hype in AMA #83
BPC-157 has three small studies with no control groups. TB-500 and GHK-Cu have animal data only. Peter Attia's AMA #83 maps what the evidence actually shows — and why the regulatory picture is shifting fast.
Your Workout May Train Your Kids Too: Peter Attia's April 2026 Research Roundup
Paternal exercise reprograms sperm microRNAs that improve offspring endurance capacity. Plus: autonomic nervous system imbalance as a unifying theory of aging. Four studies from Attia's April roundup.
Aging Clocks: What They Actually Measure (And Why Most Are Still Wrong)
Not all biological age clocks are equal. Learn why third-generation clocks like DunedinPACE outperform Horvath by orders of magnitude — and what to demand before paying for a test.
Peter Attia AMA #82: From Longevity Theory to Real-World Practice
AMA #82 shifts from mechanism to application — DEXA interpretation, wearables use, stability training, and the habits that actually stick for patients in their 40s through 60s.
Peter Attia's AMA 81: Biological Age Tests, GLP-1s, and What Actually Moves the Needle
AMA 81 covers biological age clocks, GLP-1 receptor agonists, Zone 2 training, and sun exposure — a distillation of what biohacking evidence says is worth acting on in 2026.
GRAIL's Trial Missed Its Endpoint. That's Not the Same as Failing.
Peter Attia's analysis of GRAIL's landmark cancer screening trial: a missed composite endpoint doesn't tell you whether multi-cancer early detection technology works.